BRPI0520704A2 - formulação farmacêutica absorvida oralmente e método de administração - Google Patents

formulação farmacêutica absorvida oralmente e método de administração

Info

Publication number
BRPI0520704A2
BRPI0520704A2 BRPI0520704-5A BRPI0520704A BRPI0520704A2 BR PI0520704 A2 BRPI0520704 A2 BR PI0520704A2 BR PI0520704 A BRPI0520704 A BR PI0520704A BR PI0520704 A2 BRPI0520704 A2 BR PI0520704A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
administration
formulation
aerosol
metered dose
Prior art date
Application number
BRPI0520704-5A
Other languages
English (en)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of BRPI0520704A2 publication Critical patent/BRPI0520704A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAçãO FARMACêUTICA ABSORVIDA ORALMENTE E MéTODO DE ADMINISTRAçãO. Uma formulação farmacêutica para absorção pela mucosa oral compreendendo uma quantidade efetiva de (a) um agente farmacêutico em forma micelar mista, (b) pelo menos um composto formador de micela selecionado do grupo que compreende um alquil sulfato de metal alcalino e um monooleato polioxietilênico de sorbitan, (c) um copolimero de blocos de polioxietileno e polioxipropileno, (d) pelo menos um composto adicional formador de micela e (e) um solvente adequado. A invenção também propõe um dispensador dosador (aerossol ou não aerossol) contendo a formulação da presente invenção e um método de administração de insulina usando-se o dispensador dosador compreendendo a administração de doses fracionadas de uma formulação que contém insulina antes e depois de cada refeição.
BRPI0520704-5A 2005-11-30 2005-11-30 formulação farmacêutica absorvida oralmente e método de administração BRPI0520704A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/001816 WO2007062494A1 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Publications (1)

Publication Number Publication Date
BRPI0520704A2 true BRPI0520704A2 (pt) 2009-05-19

Family

ID=38091821

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520704-5A BRPI0520704A2 (pt) 2005-11-30 2005-11-30 formulação farmacêutica absorvida oralmente e método de administração

Country Status (15)

Country Link
US (2) US20090214657A1 (pt)
EP (1) EP1954242A4 (pt)
JP (1) JP2009517410A (pt)
CN (1) CN101309668A (pt)
AP (1) AP2008004447A0 (pt)
AR (1) AR057180A1 (pt)
AU (1) AU2005338631B2 (pt)
BR (1) BRPI0520704A2 (pt)
CA (1) CA2630578C (pt)
EA (1) EA200800979A1 (pt)
EC (1) ECSP088403A (pt)
IL (1) IL191531A0 (pt)
NZ (1) NZ567601A (pt)
UY (1) UY29905A1 (pt)
WO (1) WO2007062494A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015456A1 (en) * 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101422431B (zh) * 2007-12-28 2011-03-23 上海医药工业研究院 胰岛素经鼻给药制剂
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN100594929C (zh) * 2009-06-24 2010-03-24 薛南荣 口服胰岛素药物及其制备方法
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
CA2786953A1 (en) * 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
USD645954S1 (en) * 2010-05-21 2011-09-27 Consort Medical Plc Mechanical dosage counter apparatus
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102228680B (zh) * 2011-06-14 2013-02-27 中国人民解放军第三0二医院 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂
US9119773B2 (en) * 2011-06-27 2015-09-01 Board Of Regents, The University Of Texas System Toroidal pharmaceutical formulations
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UA117480C2 (uk) 2013-04-03 2018-08-10 Санофі Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
US12108809B1 (en) 2022-04-15 2024-10-08 Air 2, LLC Aerosol pressurized delivery device and methods for manufacture and use of the same
EP4713057A1 (en) * 2023-05-15 2026-03-25 Air 2 LLC Pressurized sublingual delivery device and methods for manufacture and use of the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
EP0619730B1 (en) * 1992-10-08 2000-12-27 Supratek Pharma Inc. Composition of antineoplastic agents incorporated in micelles
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6485706B1 (en) * 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same

Also Published As

Publication number Publication date
AR057180A1 (es) 2007-11-21
US20120171259A1 (en) 2012-07-05
WO2007062494A1 (en) 2007-06-07
EA200800979A1 (ru) 2008-10-30
CN101309668A (zh) 2008-11-19
US20090214657A1 (en) 2009-08-27
AU2005338631B2 (en) 2011-12-01
AP2008004447A0 (en) 2008-04-30
IL191531A0 (en) 2008-12-29
EP1954242A4 (en) 2012-08-01
UY29905A1 (es) 2007-05-31
JP2009517410A (ja) 2009-04-30
ECSP088403A (es) 2008-05-30
NZ567601A (en) 2010-12-24
AU2005338631A1 (en) 2007-06-07
CA2630578A1 (en) 2007-06-07
CA2630578C (en) 2014-04-15
EP1954242A1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
BRPI0520704A2 (pt) formulação farmacêutica absorvida oralmente e método de administração
NO20061925L (no) Farmasoytiske preparater for forebyggelse av overdose eller misbruk
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
ES2184310T3 (es) Formulacion autoemulsionante para compuestos lipofilos acidos.
AR035348A1 (es) Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
BR9911351A (pt) Formulações farmacêuticas para aerossóis com duas ou mais substâncias ativas
IT1317846B1 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
ATE260647T1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0409440A (pt) composição farmacêutica, uso de um álcool aromático, e, métodos para intensificar a absorção de um princìpio macromolecular ativo em um paciente e para tratar um paciente que esteja sofrendo de uma condição ou doença
UY28366A1 (es) Compuestos químicos
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
WO2003020214A3 (en) Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
TNSN07289A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
WO2007020204A3 (en) Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
UA90346C2 (ru) Фармацевтическая рецептура для перорального приема и способ введения пациенту
WO2007011958A3 (en) Intraoral dosage forms of glucagon
TW200634002A (en) Chemical compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.